Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $37.71.
A number of analysts have issued reports on the company. UBS Group raised their price target on Akero Therapeutics from $39.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, March 5th. HC Wainwright raised their price target on Akero Therapeutics from $40.00 to $43.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Finally, Bank of America assumed coverage on Akero Therapeutics in a research note on Monday. They issued a “neutral” rating and a $30.00 price target on the stock.
View Our Latest Stock Analysis on AKRO
Insiders Place Their Bets
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in AKRO. RTW Investments LP acquired a new position in Akero Therapeutics during the 4th quarter valued at approximately $83,891,000. Wellington Management Group LLP boosted its position in Akero Therapeutics by 247.7% during the 4th quarter. Wellington Management Group LLP now owns 2,881,989 shares of the company’s stock valued at $67,294,000 after purchasing an additional 2,053,028 shares during the period. Lord Abbett & CO. LLC boosted its position in Akero Therapeutics by 154.4% during the 3rd quarter. Lord Abbett & CO. LLC now owns 779,126 shares of the company’s stock valued at $39,409,000 after purchasing an additional 472,898 shares during the period. Fred Alger Management LLC boosted its position in Akero Therapeutics by 3,100.2% during the 3rd quarter. Fred Alger Management LLC now owns 441,086 shares of the company’s stock valued at $22,310,000 after purchasing an additional 427,303 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in Akero Therapeutics by 225.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 500,245 shares of the company’s stock valued at $25,302,000 after purchasing an additional 346,317 shares during the period.
Akero Therapeutics Stock Down 3.5 %
Akero Therapeutics stock opened at $20.26 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 29.27 and a current ratio of 29.27. The firm has a market capitalization of $1.40 billion, a price-to-earnings ratio of -7.11 and a beta of -0.38. Akero Therapeutics has a fifty-two week low of $11.25 and a fifty-two week high of $58.38. The stock’s fifty day moving average is $24.73 and its two-hundred day moving average is $20.98.
Akero Therapeutics (NASDAQ:AKRO – Get Free Report) last posted its earnings results on Thursday, February 29th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.17). Analysts predict that Akero Therapeutics will post -4.06 EPS for the current fiscal year.
Akero Therapeutics Company Profile
Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
Read More
- Five stocks we like better than Akero Therapeutics
- Using the MarketBeat Dividend Tax Calculator
- High-Yield Texas Instruments Could Hit New Highs Soon
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Best Aerospace Stocks Investing
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.